Technical Note

Kidney International (1989) 35, 1413–1417; doi:10.1038/ki.1989.142

Influence of dietary constituents on intestinal absorption of aluminum

Neil A Partridge1, Fred E Regnier1, Joe L White1 and Stanley L Hem1

1 Departments of Industrial and Physical Pharmacy, Biochemistry and Agronomy, Purdue University, West Lafayette, Indiana, USA

Correspondence: Stanley L Hem PhD, Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, Indiana 47097, USA.

Received 13 May 1988; Revised 17 January 1989; Accepted 27 January 1989.

Top

Abstract

Orally-ingested aluminum compounds have been implicated in the development of dialysis encephalopathy, osteomalacic dialysis osteodystrophy and other disorders in both hemodialyzed and nonhemodialyzed patients suffering from chronic renal failure [1–10]. Both dialysate aluminum content [7, 11, 12] and aluminum-containing phosphate binding agents [12–15] have been identified as contributing to hyperaluminemia in uremic patients. The health threat from dialysate fluids has been reduced by the recommendation that the dialysate contains less than 10 microg/liter of aluminum [16]. Alternative phosphate-binding agents which do not contain aluminum are available but these agents are not free of problems [17], and uremic patients continue to ingest significant doses of aluminum-containing phosphate binding agents.

Aluminum is the most common metal in the biosphere of humans but, aside from uremic patients, causes no widespread toxicity. This may be as a result of the extremely limited solubility of aluminum at the pH range of the small intestine and blood [18]. Advances in analytical chemistry have made it possible to measure picogram quantities of aluminum in body fluids, thus enabling accurate determination of plasma aluminum levels in the part per billion (microg/liter) range. These analytical techniques have shown that orally ingested aluminum-containing antacids elevate plasma aluminum levels in man [13]. Balance studies monitoring aluminum absorption and elimination revealed an average positive balance from 23 to 313 mg of aluminum per day when diets were supplemented with 1 to 3 g of aluminum per day [15]. These studies show that a small fraction of the ingested aluminum is absorbed. This absorption presents potential toxic effects to uremic patients whose ability to eliminate aluminum is impaired.

In addition, Slanina et al [19] have shown that addition of citric acid to aluminum-supplemented dietary regimens results in blood aluminum levels that are significantly higher than those found in subjects treated with aluminum-supplemented dietary regimens alone. This result suggests that dietary factors may contribute to aluminum absorption.

This study was undertaken to determine if the form of aluminum present in the intestinal lumen significantly affects the absorption of aluminum following oral ingestion.

Top

References

  1. Alfrey AC, LeGendre GR, Kaehny WD: Dialysis encephalopathy syndrome. N Engl J Med 294:184–188, 1976 | PubMed | ISI | ChemPort |
  2. Parkinson IS, Ward MK, Feest TG, Fawcett RWP, Kerr DNS: Fracturing dialysis osteodystrophy and dialysis encephalopathy. Lancet 1:406–409, 1979
  3. Arieff AI, Cooper JD, Armstrong D, Lazarowitz VC: Dementia, renal failure, and brain aluminum. Ann Intern Med 90:741–747, 1979
  4. Berlyne GM, Ben-Ari J, Pest D, Weinberger J, Stern M, Gilmore GR, Levine R: Hyperaluminaemia from aluminum resins in renal failure. Lancet 1:494–496, 1970
  5. McDermott JR, Smith AI, Ward MK, Parkinson IS, Kerr DNS: Brain-aluminum concentration in dialysis encephalopathy. Lancet 1:901–904, 1978
  6. Dunea G, Mahurkar SD, Mamdani B, Smith EC: Role of aluminum in dialysis dementia. Ann Intern Med 88:502–504, 1978
  7. Ward MK, Feest TG, Ellis HA, Parkinson LS, Kerr DNS, Herrington J, Goode GL: Osteomalacic dialysis osteodystrophy: Evidence for a water-borne aetiological agent, probably aluminum. Lancet 1:841–845, 1978
  8. Ellis HA, McCarthy JH, Herrington J: Bone aluminum in haemodialised patients and rats injected with aluminum chloride: Relationship to impaired bone mineralization. J Clin Pathol 32:832–844, 1978
  9. Cournot-Witmer G, Zingraff J, Bourdon R, Drueke T, Balsan S: Aluminium and dialysis bone disease. Lancet 2:795–796, 1979
  10. Clarkson EM, Luk VA, Hynson WV, Bailey RR, Eastwood JB, Woodhead JS, Clements VR, O'Riordan JLH, DeWardener HE: The effect of aluminum hydroxide on calcium, phosphorus, and aluminum balances: The serum parathyroid hormone concentration; and the aluminum content of bone in patients with chronic renal failure. Clin Sci 43:519–531, 1972 | PubMed |
  11. Berlyne GM, Rubin JE: Aluminum ion: Metabolism and toxicity. J Hum Nutr 31:439–442, 1977
  12. Kaehny WD, Alfrey AC, Holman RE, Shorr WJ: Aluminum transfer during hemodialysis. Kidney Int 12:361–365, 1977 | PubMed |
  13. Kaehny WD, Hegg AP, Alfrey AC: Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296:1389–1390, 1977 | PubMed |
  14. Graf H, Stummvoll HK, Meisinger V, Kovarik J, Wolf A, Pinggera WF: Aluminum removal by hemodialysis. Kidney Int 19:587–592, 1981
  15. Gorsky JE, Dietz AA, Spencer A, Osis D, : Metabolic balance of aluminum studied in six men. Clin Chem 25:1739–1743, 1979
  16. Alfrey AC: Aluminum metabolism. Kidney Int (suppl) 29:S8–S11, 1986
  17. Fournier A, Moriniere P, Sebert JL, Dkhissi H, Atik A, Leflon P, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M: Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia. Kidney Int (suppl) 29:S114–S119, 1986
  18. Martin RD: Chemistry of aluminum as related to biology and medicine. Clin Chem 32:1797–1806, 1986
  19. Slanina P, Frech W, Ekstrom L, Loof L, Slorach S, Cedergren A: Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem 32:539–541, 1986
  20. Doluisio JT, Billips NF, Dittert LW, Sugita ET, Swintowksy JV: Drug absorption I: An in-situ rat gut technique yielding realistic absorption rates. J Pharm Sci 58:1196–1200, 1969
  21. Slanina P, Falkeborn Y: Aluminum concentrations in the brain and bone of rats fed citric acid, aluminum citrate or aluminum hydroxide. Food Chem Toxicol 22:391–397, 1984
  22. Larson EA, Ash SR, White JL, Hem SL: Phosphate binding gels: Balancing phosphate adsorption and aluminum toxicity. Kidney Int 29:1131–1135, 1986
  23. Carlson GL, Malagelada JR: Chemistry of the antacids: Its relevance to antacid therapy, in Antacids in the Eighties, edited by Halter F, Baltimore, Urban and Schwarzenberg, 1982
  24. Hem SL, White JL: Stable dried aluminum hydroxide gel. U.S. Patent 4,059,681, November, 22, 1977
  25. Leung FY, Henderson AR: Improved determination of aluminum in serum and urine with use of stabilized temperature platform furnace. Clin Chem 28:2139–2143, 1982
  26. Roberson CE, Hem JD: Solubility of Aluminum in the Presence of Hydroxide, Fluoride, and Sulfate. Geological survey water-supply paper 1827-C, United States Government Printing Office, Washington, D.C., 1969
  27. Serna CJ, Lyons JC, White JL, Hem SL: Stabilization of aluminum hydroxide gel by specifically adsorbed carbonate. J Pharm Sci 72:769–771, 1983
  28. Ting SV: Nutrients and Nutrition of Citrus Fruits, in Citrus Nutrition and Quality, edited by Nagy S, Attaway JA, American Chemical Society, Washington, D.C., 1980
  29. Food and Agriculture Organization of the United Nations: Food and Nutrition Paper No.30. Rome, 1984

Extra navigation

.
ADVERTISEMENT